Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Healthcare Sector Analysis

UpdatedNov 04, 2025
DataAggregated Company Financials
Companies34
  • 7D-2.1%
  • 3M1.6%
  • 1Y-0.6%
  • YTD4.6%

Over the last 7 days, the Healthcare industry has dropped 2.1%, driven by Novartis declining 3.5%. On the other hand Galderma Group is actually up 8.4%. As for the longer term, the industry's performance has been flat for the past year. As for the next few years, earnings are expected to grow by 14% per annum.

Sector Valuation and Performance

Has the Swiss Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 04 Nov 2025CHF 603.0bCHF 155.4bCHF 25.0b30.1x24.2x3.9x
Thu, 02 Oct 2025CHF 622.9bCHF 153.6bCHF 24.2b32x25.7x4.1x
Sat, 30 Aug 2025CHF 610.9bCHF 153.9bCHF 24.3b33.2x25.2x4x
Mon, 28 Jul 2025CHF 601.5bCHF 152.9bCHF 24.1b31.2x25x3.9x
Wed, 25 Jun 2025CHF 584.1bCHF 150.5bCHF 22.3b30.4x26.2x3.9x
Fri, 23 May 2025CHF 574.3bCHF 152.2bCHF 22.6b30.9x25.4x3.8x
Sun, 20 Apr 2025CHF 545.7bCHF 149.9bCHF 21.8b25.9x25.1x3.6x
Tue, 18 Mar 2025CHF 629.0bCHF 154.8bCHF 22.4b31.6x28.1x4.1x
Thu, 13 Feb 2025CHF 630.5bCHF 156.6bCHF 22.5b30x28x4x
Sat, 11 Jan 2025CHF 589.7bCHF 153.6bCHF 24.7b30.1x23.9x3.8x
Mon, 09 Dec 2024CHF 571.1bCHF 150.7bCHF 24.2b28.9x23.6x3.8x
Wed, 06 Nov 2024CHF 595.8bCHF 149.3bCHF 24.0b29.9x24.8x4x
Fri, 04 Oct 2024CHF 601.1bCHF 147.6bCHF 22.4b32.9x26.8x4.1x
Sun, 01 Sep 2024CHF 631.7bCHF 147.3bCHF 22.4b32.7x28.3x4.3x
Tue, 30 Jul 2024CHF 615.4bCHF 149.3bCHF 22.6b31.7x27.3x4.1x
Thu, 27 Jun 2024CHF 576.8bCHF 148.9bCHF 22.7b35.1x25.4x3.9x
Sat, 25 May 2024CHF 557.3bCHF 150.2bCHF 22.9b33.6x24.3x3.7x
Mon, 22 Apr 2024CHF 539.2bCHF 145.0bCHF 22.3b35.3x24.2x3.7x
Wed, 20 Mar 2024CHF 532.7bCHF 143.6bCHF 22.2b37.3x24x3.7x
Fri, 16 Feb 2024CHF 518.3bCHF 142.7bCHF 22.4b32.9x23.2x3.6x
Sun, 14 Jan 2024CHF 544.6bCHF 151.4bCHF 21.8b27.5x25x3.6x
Tue, 12 Dec 2023CHF 524.2bCHF 153.4bCHF 22.0b25.5x23.8x3.4x
Thu, 09 Nov 2023CHF 506.0bCHF 154.7bCHF 22.1b23.8x22.9x3.3x
Sat, 07 Oct 2023CHF 532.1bCHF 145.7bCHF 21.2b31.9x25.1x3.7x
Mon, 04 Sep 2023CHF 545.5bCHF 144.3bCHF 21.1b29.8x25.8x3.8x
Wed, 02 Aug 2023CHF 561.4bCHF 146.7bCHF 22.5b36.5x24.9x3.8x
Fri, 30 Jun 2023CHF 560.7bCHF 147.4bCHF 22.3b35x25.2x3.8x
Sun, 28 May 2023CHF 579.0bCHF 147.7bCHF 22.3b35x26x3.9x
Tue, 25 Apr 2023CHF 590.1bCHF 146.2bCHF 22.3b34.2x26.5x4x
Thu, 23 Mar 2023CHF 532.8bCHF 148.2bCHF 22.5b30.8x23.6x3.6x
Sat, 18 Feb 2023CHF 547.3bCHF 148.1bCHF 22.8b32.2x24x3.7x
Mon, 16 Jan 2023CHF 567.5bCHF 148.6bCHF 38.1b30.7x14.9x3.8x
Wed, 14 Dec 2022CHF 578.8bCHF 148.6bCHF 38.1b31.7x15.2x3.9x
Fri, 11 Nov 2022CHF 591.9bCHF 150.8bCHF 38.9b29x15.2x3.9x
Price to Earnings Ratio

15.2x


Total Market Cap: CHF 591.9bTotal Earnings: CHF 38.9bTotal Revenue: CHF 150.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Healthcare Sector Price to Earnings3Y Average 24.3x202320242025
Current Industry PE
  • Investors are relatively neutral on the Swiss Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 24.3x.
  • The industry is trading close to its 3-year average PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 14% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare sector?

CH Market-1.66%
Healthcare-2.06%
Biotech1.77%
Medical Equipment-0.10%
Healthtech-1.64%
Pharma-1.84%
Healthcare Services-3.25%
Life Sciences-6.66%
Industry PE
  • Investors are most optimistic about the Life Sciences industry, which is trading close to its 3-year average PE ratio of 45.3x.
    • Analysts expect its future annual earnings growth (20.3%) to be largely in line with prior year's earnings growth.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 40% over the next 5 years.
  • This is better than its past earnings decline of 80% per year.
  • In contrast, the Healthcare Services industry is expected to see its earnings grow by 5.3% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVN NovartisCHF 101.482.6%
+CHF 5.0b		8.0%PE16.7x
GALD Galderma GroupCHF 153.307.3%
+CHF 2.5b		85.1%PE119x
ROG Roche HoldingCHF 264.001.1%
+CHF 2.5b		-1.6%PE23.8x
SDZ Sandoz GroupCHF 54.9810.6%
+CHF 2.3b		37.7%PE128.9x
STMN Straumann HoldingCHF 98.1412.1%
+CHF 1.7b		-16.9%PE36.6x

Latest News

ROG
CHF 264.00
Roche Holding
7D
1.1%
1Y
-1.6%
STMN
CHF 98.14
Straumann Holding
7D
12.1%
1Y
-16.9%

STMN: Future Performance Will Depend On U S Operational Recovery And Margin Stability

Straumann Holding's analyst price target saw a modest decrease to CHF 111.29 from CHF 111.58, as analysts weighed improving U.S. operational trends in contrast with ongoing concerns over slower revenue growth and margin adjustments. Analyst Commentary Analysts remain divided on the outlook for Straumann Holding, highlighting both areas of growing confidence and lingering concerns regarding the company's performance and prospects.
NOVN
CHF 101.48
Novartis
7D
2.6%
1Y
8.0%

NOVN: Future Trial Data And Pipeline Advancements Will Support Steady Returns

Analysts have raised their fair value estimate for Novartis from $98.60 to $102.12. They cite improved revenue growth outlook and stronger profit margins as key drivers of the upward revision.
TECN
CHF 140.20
Tecan Group
7D
-4.8%
1Y
-36.3%

TECN: Resilient Demand And Share Repurchase Program Will Drive Shareholder Value

The analyst price target for Tecan Group has been revised downward from CHF 177 to CHF 170. Analysts cite slightly softer revenue growth expectations and a modest increase in the discount rate in their updated assessments.
SOON
CHF 215.70
Sonova Holding
7D
-3.6%
1Y
-33.2%

SOON: Market Resilience Will Be Tested By Rising Competition And End Market Weakness

Analysts have lowered their average price target for Sonova Holding from CHF 246.65 to CHF 242.47. This reflects a more cautious outlook amid concerns over softer end markets and increased competition.
GALD
CHF 153.30
Galderma Group
7D
7.3%
1Y
85.1%

GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside

The fair value estimate for Galderma Group has been raised to CHF 149.91 from CHF 142.41. This change reflects analysts' increased confidence due to positive revisions to growth and margin forecasts, as well as a series of upward price target adjustments from major research firms.
GALE
CHF 87.50
Galenica
7D
1.2%
1Y
16.3%

GALE: Stable Outlook As Digital And In-Store Investments Will Support 2025 Guidance

Galenica's analyst price target remains unchanged at CHF 85.50. Analysts cite minimal revisions to growth and margin assumptions since the previous update.
SKAN
CHF 49.60
SKAN Group
7D
-5.3%
1Y
-36.6%

These 4 Measures Indicate That SKAN Group (VTX:SKAN) Is Using Debt Extensively

Oct 29
These 4 Measures Indicate That SKAN Group (VTX:SKAN) Is Using Debt Extensively
ALC
CHF 60.72
Alcon
7D
2.1%
1Y
-24.1%

Cutting Edge Eye Care Solutions Will Transform Outcomes For Global Aging Populations

Alcon's analyst price target has been revised slightly downward, decreasing by $1.25 to $79.17. Analysts have adjusted their expectations to reflect slightly lower revenue growth and profit margin forecasts.
SFZN
CHF 76.00
Siegfried Holding
7D
-3.3%
1Y
-32.5%

Does Siegfried Holding (VTX:SFZN) Deserve A Spot On Your Watchlist?

Oct 26
Does Siegfried Holding (VTX:SFZN) Deserve A Spot On Your Watchlist?
SDZ
CHF 54.98
Sandoz Group
7D
10.6%
1Y
37.7%

Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach

The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.
BANB
CHF 53.70
Bachem Holding
7D
-7.5%
1Y
-28.0%

Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings

Oct 25
Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings
LONN
CHF 540.00
Lonza Group
7D
-5.3%
1Y
-0.7%
YPSN
CHF 308.50
Ypsomed Holding
7D
-0.8%
1Y
-22.9%

Analysts Revise Ypsomed Target Downward Amid Mixed Views on Growth and Margins

The analyst consensus price target for Ypsomed Holding has been revised downward by CHF 8.33 to CHF 421.59, as analysts cite slightly moderated growth prospects and profit margins. This comes despite continued optimism about the company's leadership in the high-growth injectables market.
KURN
CHF 30.18
Kuros Biosciences
7D
3.6%
1Y
8.2%

Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts

Oct 18
Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts
DESN
CHF 314.00
Dottikon ES Holding
7D
-2.3%
1Y
31.1%

If EPS Growth Is Important To You, Dottikon ES Holding (VTX:DESN) Presents An Opportunity

Oct 10
If EPS Growth Is Important To You, Dottikon ES Holding (VTX:DESN) Presents An Opportunity